Darzi Fellowship to use community pharmacy for the first time

A Darzi Fellowship for 2017/18 has been approved for UCLH Cancer Collaborative to work with LloydsPharmacy to evaluate the implications of delivering subcutaneous hormonal injections for breast and prostate cancer via a community pharmacist model.  This is the first time that a Darzi Fellowship in Clinical Leadership will involve community pharmacy.

The output of the one year project, called The Delivery of Hormonal and other Cancer therapies by Community Pharmacists, will be a toolkit guide to delivering hormonal treatments via the community pharmacy setting.  The Fellow will review and compare the financial reimbursement and costs associated with treating these cancer patients at UCLH (University College London Hospitals NHS Foundation Trust) relative to the community costs.  The Fellow will also conduct focus groups and in-depth interviews with different professional groups and patients to understand the enablers and barriers when delivering care via the community pharmacy route. These groups will include clinicians, clinical nurse specialists, pharmacists in the community and commissioning leads.

The Darzi Fellowship Programme is designed to develop the next generation of senior clinical leaders in health and social care by providing them with work-based experience in a new environment, as well as a Masters Level Leadership Development programme, focused on leading complex change.  Proposals for Darzi Fellows are reviewed competitively by the Health Education England (HEE) Darzi Assessment Panel and are selected based on their alignment with the Five Year Forward View and local Sustainability and Transformation Plan, potential impact and leadership development opportunities.

Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, said:  “The delivery of cancer treatment closer to home is a national priority. Many patients living with and beyond cancer still require some type of ‘maintenance’ treatment to reduce the risk of complications of treatment or of disease recurrence. The current model of care means that a patient will need to travel to their acute hospital to receive monthly treatments that are relatively simple to administer in the community.

“Community pharmacists have recently expanded their areas of expertise and demonstrated competence in injecting travel and flu vaccines. There is currently a drive to improve the specialism within community pharmacy to address the needs of cancer patients.

“Administration closer to home would not only have benefits for patients but also may provide NHS cost savings. Delivery of subcutaneous injections that are not active chemotherapy are costly to both the commissioner and the acute provider. This project will determine the cost implications of delivering hormonal and simple supportive care treatment by community pharmacists.”

Jill Pritchard, head of speciality pharmacy at Celesio UK (which includes LloydsPharmacy) said:  “We are actively looking at how we work with the NHS to deliver new models of care.  Pharmacists have proved that they have the skills and expertise to conduct injection programmes and LloydsPharmacy stores, as they are based in communities, are an ideal and accessible location for patients.  This project has the potential to revolutionise cancer care and potentially deliver cost savings to the NHS.”

Ends

Media enquiries:

LloydsPharmacy                             Claire Salmons 024 7662 5530

UCLH Cancer Collaborative         Joanna Clason 07775 690825

 

Notes to editors

About LloydsPharmacy

LloydsPharmacy has around 1,800 pharmacies across the UK. These are based predominantly in community and health centre locations and include 277 LloydsPharmacy in Sainsbury’s branches. The company employs over 19,000 staff and dispenses more than 150 million prescription items annually.

LloydsPharmacy is part of the Celesio Group; a leading international pharmaceutical wholesale and retail pharmacy company.

With strong brands and about 37,000 employees, the group is active in 13 European countries (thereof with own operations in ten countries; Celesio manages operations in two countries and participates in a joint venture in one country). Every day, the company serves over 2 million customers – at more than 2,150 pharmacies of its own, at about 300 managed pharmacies and at over 4,500 participants in the brand partnership schemes. With 107 wholesale branches in Europe, Celesio supplies more than 50,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products.

McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

McKesson is a Fortune-500 company and currently ranking #5.

About UCLH Cancer Collaborative

  1. UCLH Cancer Collaborative brings together healthcare organisations across north central and north east London, and west Essex to improve early cancer diagnosis, cancer outcomes and care for patients.  We are part of the national Cancer Vanguard – a partnership between the UCLH Cancer Collaborative, Greater Manchester Cancer Vanguard Innovation and Royal Marsden Partners. Visit our webpages: www.uclh.nhs.uk/cancercollaborative
  2. UCLH (University College London Hospitals NHS Foundation Trust), situated in the West End of London, is one of the largest NHS trusts in the United Kingdom and provides first-class acute and specialist services. Visit our website www.uclh.nhs.uk, we are also on Facebook (UCLHNHS), Twitter (@UCLH) and Youtube (UCLHvideo).
  3. For more information contact Joanna Clason on 07775690825. For out of hours media enquiries, please call the duty press officer on 077 1249 0702.
  4. Twitter #uclhcancer #cancervanguard